Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Butirprost as Adjuvant to Levofloxacin in Chronic Bacterial Prostatitis
NCT06684626Phase 3Completed
- Sponsor
- University of Naples Federico II
- Start
- Mar 2024
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in chronic bacterial prostatitis (CBP) (2 arms), sponsored by University of Naples Federico II. Primary endpoints: Change in pain at 30 days, Change in urinary symptoms at 30 days and 1 more. Started Mar 2024; status: completed.
02
Conditions
chronic bacterial prostatitis (CBP)
Beyond the preview
Go deeper on NCT06684626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06684626.